Paper Title

AN UPDATE ON PATHOPHYSIOLOGY AND MANAGEMENT OF ALZHEIMER’S DISEASE

Article Identifiers

Registration ID: IJNRD_202048

Published ID: IJNRD2307312

DOI: Click Here to Get

Authors

Dr. Charulata Tushar Nemade , Tejal Mahale , Vishakha Gangwal , Akshada Shinde , Hitesh V. Shahare

Keywords

Keywords: Alzheimer's disease; memory; cholinergic hypothesis; cerebral spinal fluid; Tacrine; antioxidants

Abstract

ABSTRACT Alzheimer's disease (AD), the most common neurodegenerative condition, produces growing problems in memory, cognition, and behaviour and ultimately leads in death. In addition to neuronal and synaptic loss, intracellular neurofibrillary tangles and extracellular senile plaques also develop in the brain as a result of Alzheimer's disease. Alzheimer's disease, the most common form of dementia, is the only one of the top 10 causes of death in the US for which there is no effective treatment. Numerous studies show that factors such as age, some genetic components, diet, and nutrition all raise the risk of AD. Several hypotheses explain the pathophysiology of AD includingamyloid cascade hypothesis, Tau hypothesis, cholinergic hypothesis, mitochondrial cascade theory, metabolic hypothesis. Genetic factors play a role in the development ofAlzheimer's disease; characterised by insulin/IGF resistance and insufficiency in the brain.In mild Alzheimer's disease patient suffers memory loss that disrupts daily life, losing track of dates or knowing current location etc. while in severe cases patient in unable to communicate, have no awareness of recent experiences or surroundings, increased sleeping, loss of bowel and bladder control etc. Alzheimer's, physicians may use medical history, mental status tests, physical and neurological exams, diagnostic tests and brain imaging to diagnose the disease. Cerebral spinal fluid tests for low beta-amyloid 42 and increased tau is helpful to diagnose preclinical stage AD treatment aims to enhance the patient's functioning and quality of life. Tacrine, donepezil, galantamine, and rivastigmine are the four medications that have received FDA approval for the treatment of Alzheimer's disease. In this overview, we discuss the various theories regarding its onset, symptoms, and treatments, including cholinesterase inhibitors, beta-amyloid ligands, antioxidants, antipsychotics, novel drug delivery systems, and the effects of diet and exercise on AD.

How To Cite (APA)

Dr. Charulata Tushar Nemade, Tejal Mahale, Vishakha Gangwal, Akshada Shinde, & Hitesh V. Shahare (July-2023). AN UPDATE ON PATHOPHYSIOLOGY AND MANAGEMENT OF ALZHEIMER’S DISEASE. INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT, 8(7), d93-d106. https://ijnrd.org/papers/IJNRD2307312.pdf

Issue

Volume 8 Issue 7, July-2023

Pages : d93-d106

Other Publication Details

Paper Reg. ID: IJNRD_202048

Published Paper Id: IJNRD2307312

Downloads: 000121978

Research Area: Pharmacy

Country: Nashik, Maharashtra, India

Published Paper PDF: https://ijnrd.org/papers/IJNRD2307312.pdf

Published Paper URL: https://ijnrd.org/viewpaperforall?paper=IJNRD2307312

About Publisher

Journal Name: INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT(IJNRD)

ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar | ESTD YEAR: 2016

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Publisher: IJNRD (IJ Publication) Janvi Wave | IJNRD.ORG | IJNRD.COM | IJPUB.ORG

Publication Timeline

Peer Review
Through Scholar9.com Platform

Article Preview: View Full Paper

Call For Paper

Call For Paper - Volume 10 | Issue 10 | October 2025

IJNRD is a Scholarly Open Access, Peer-reviewed, and Refereed Journal with a High Impact Factor of 8.76 (calculated by Google Scholar & Semantic Scholar | AI-Powered Research Tool). It is a Multidisciplinary, Monthly, Low-Cost Journal that follows UGC CARE 2025 Peer-Reviewed Journal Policy norms, Scopus journal standards, and Transparent Peer Review practices to ensure quality and credibility. IJNRD provides indexing in all major databases & metadata repositories, a citation generator, and Digital Object Identifier (DOI) for every published article with full open-access visibility.

The INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) aims to advance applied, theoretical, and experimental research across diverse fields. Its goal is to promote global scientific information exchange among researchers, developers, engineers, academicians, and practitioners. IJNRD serves as a platform where educators and professionals can share research evidence, models of best practice, and innovative ideas, contributing to academic growth and industry relevance.

Indexing Coverage includes Google Scholar, SSRN, ResearcherID-Publons, Semantic Scholar (AI-Powered Research Tool), Microsoft Academic, Academia.edu, arXiv.org, ResearchGate, CiteSeerX, ResearcherID (Thomson Reuters), Mendeley, DocStoc, ISSUU, Scribd, and many more recognized academic repositories.

How to submit the paper?

Important Dates for Current issue

Paper Submission Open For: October 2025

Current Issue: Volume 10 | Issue 10 | October 2025

Impact Factor: 8.76

Last Date for Paper Submission: Till 31-Oct-2025

Notification of Review Result: Within 1-2 Days after Submitting paper.

Publication of Paper: Within 01-02 Days after Submititng documents.

Frequency: Monthly (12 issue Annually).

Journal Type: IJNRD is an International Peer-reviewed, Refereed, and Open Access Journal with Transparent Peer Review as per the new UGC CARE 2025 guidelines, offering low-cost multidisciplinary publication with Crossref DOI and global indexing.

Subject Category: Research Area

Call for Paper: More Details